The P.K. Shah Laboratory research is focused on identifying novel molecular mechanisms and pathways leading to inflammation and atherosclerosis and developing novel therapies to prevent, stabilize and reverse atherosclerosis. Current investigations include:
- Identifying novel molecular mechanisms and pathways in the pathophysiology of atherosclerotic cardiovascular disease
- Developing novel gene-based therapies for prevention, stabilization and reversal of atherosclerosis
- Defining the role of autoimmunity in atherosclerosis and developing a vaccine for atherosclerosis, aortic aneurysm and hypertension
As director of the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai and PI of the Prediman Krishan (P. K.) Shah Laboratory, I am leading several studies that focus on heart disease prevention and treatment. Our lab has discovered the atheroprotective and atheroregressive effects of recombinant mutant apolipoprotein (ApoA-I Milano) and led its development into a therapeutic strategy."
The P. K. Shah Laboratory has identified a number of novel genes such as tenascin C, pleotrophin (PTN), GATA3 and KLF14 that have potential implications for inflammation, atherosclerosis and obesity-metabolic syndrome. We are currently evaluating their role in murine models of atherosclerosis, myocardial infarction, left ventricular remodeling and obesity.
Meet Our Team
Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Shah Laboratory, whose dedicated efforts lead to groundbreaking discoveries.
Honjo T, Chyu KY, Dimayuga PC, Yano J, Lio WM, Trinidad P, Zhao X, Zhou J, Chen S, Cercek B, Arditi M, Shah PK.
J Am Coll Cardiol. 2015 Feb 17;65(6):546-556.
Shah PK, Chyu KY, Dimayuga PC, Nilsson J.
J Am Coll Cardiol. 2014 Dec 30;64(25):2779-2791.
Tian F, Wang L, Arias A, Yang M, Sharifi BG, Shah PK.
J Cardiovasc Pharmacol Ther. 2015 Jan;20(1):66-75.